Journal ArticleDOI
MitraClip® therapy in patients with end-stage systolic heart failure.
Olaf Franzen,Jan Van der Heyden,Stephan Baldus,Michael Schlüter,Wolfgang Schillinger,Christian Butter,Rainer Hoffmann,Roberto Corti,Giovanni Pedrazzini,Martin J. Swaans,Michael Neuss,Volker Rudolph,Daniel Sürder,Jürg Grünenfelder,Christine Eulenburg,Hermann Reichenspurner,Thomas Meinertz,Angelo Auricchio +17 more
TLDR
To assess the feasibility, short‐term durability and clinical outcomes of MitraClip therapy for mitral regurgitation (MR) in patients with end‐stage heart failure and a severely reduced left ventricular ejection fraction, data are presented.Abstract:
Aims To assess the feasibility, short-term durability and clinical outcomes of MitraClip (R) therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction. Methods and results We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [ mean age 70 +/- 11 years, 38 men (76%)] with a LV ejection fraction Conclusion MitraClip (R) therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.read more
Citations
More filters
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: The medical profession should play a central role in evaluating the evidence related to drugs, according to a report by the World Health Organization and the European Medicines Agency.
Journal ArticleDOI
Percutaneous Mitral Valve Interventions in the Real World: Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in Europe
Francesco Maisano,Olaf Franzen,Stephan Baldus,Ulrich Schäfer,Jörg Hausleiter,Christian Butter,Gian Paolo Ussia,Horst Sievert,Gert Richardt,Julian D. Widder,Tiziano Moccetti,Wolfgang Schillinger +11 more
TL;DR: In the real-world, post-approval experience in Europe, patients undergoing the MitraClip therapy are high-risk, elderly patients, mainly affected by functional MR, and in this patient population, the MitRAClip procedure is effective with low rates of hospital mortality and adverse events.
Journal ArticleDOI
Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association
Larry A. Allen,Lynne W. Stevenson,Kathleen L. Grady,Nathan E. Goldstein,Daniel D. Matlock,Robert M. Arnold,Nancy R. Cook,G. Michael Felker,Gary S. Francis,Paul J. Hauptman,Edward P. Havranek,Harlan M. Krumholz,Donna M. Mancini,Barbara Riegel,John A. Spertus +14 more
TL;DR: Shared decision making for advanced heart failure has become both more challenging and more crucial as duration of disease and treatment options have increased as mentioned in this paper, and the ethical and legal mandate to involve patients in medical decisions has become more and more challenging.
Journal ArticleDOI
Percutaneous Mitral Valve Edge-to-Edge Repair: In-Hospital Results and 1-Year Follow-Up of 628 Patients of the 2011–2012 Pilot European Sentinel Registry
Georg Nickenig,Rodrigo Estévez-Loureiro,Olaf Franzen,Corrado Tamburino,Marc Vanderheyden,Thomas F. Lüscher,Neil Moat,Susanna Price,Gianni Dall'Ara,Reidar Winter,Roberto Corti,Carmelo Grasso,Thomas Snow,Raban Jeger,Stefan Blankenberg,Magnus Settergren,Klaus Tiroch,Jan Balzer,Anna Sonia Petronio,Heinz-Joachim Büttner,Federica Ettori,Horst Sievert,Maria Giovanna Fiorino,Marc J. Claeys,Gian Paolo Ussia,Helmut Baumgartner,Salvatore Scandura,Farqad Alamgir,Freidoon Keshavarzi,Antonio Colombo,Francesco Maisano,Henning Ebelt,Patrizia Aruta,Edith Lubos,Björn Plicht,Robert Schueler,Michele Pighi,Carlo Di Mario +37 more
TL;DR: This independent, contemporary registry shows that TMVR is associated with high immediate success, low complication rates, and sustained 1-year reduction of the severity of mitral regurgitation and improvement of clinical symptoms.
References
More filters
Journal ArticleDOI
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography
William A. Zoghbi,Maurice Enriquez-Sarano,Elyse Foster,Paul A. Grayburn,Carol D. Kraft,Robert A. Levine,Petros Nihoyannopoulos,Catherine M Otto,Miguel A. Quinones,Harry Rakowski,William J. Stewart,Alan D. Waggoner,Neil J. Weissman +12 more
TL;DR: A report from the American Society of Echocardiography’s Nomenclature and Standards Committee and The Task Force on Valvular Regurgitation developed in conjunction with the American College of Cardiology EchOCardiography Committee.
Journal ArticleDOI
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Sharon A. Hunt,William T. Abraham,Marshall H. Chin,Arthur M. Feldman,Gary S. Francis,Theodore G. Ganiats,Mariell Jessup,Marvin A. Konstam,Donna Mancini,Keith Michl,John A. Oates,Peter S. Rahko,Marc A. Silver,Lynne W. Stevenson,Clyde W. Yancy +14 more
TL;DR: Theodore G. Feldman, MD, PhD, FACC, FAHA, Chair as mentioned in this paper, Chair, Chair of FAHA 2015, 2016, 2017, 2018, 2019, 2019
Journal ArticleDOI
Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure
Eric A. Rose,Annetine C. Gelijns,Alan J. Moskowitz,Daniel F. Heitjan,L.W. Stevenson,W Dembitsky,J W Long,D D Ascheim,Anita R. Tierney,R G Levitan,John T. Watson,P Meier,Nuala S. Ronan,P A Shapiro,Ronald M. Lazar,Leslie W. Miller,L Gupta,O.H. Frazier,Patrice Desvigne-Nickens,Mehmet C. Oz,V L Poirier +20 more
TL;DR: The use of a left ventricular assist device in patients with advanced heart failure resulted in a clinically meaningful survival benefit and an improved quality of life.
Journal ArticleDOI
Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort.
Ted Feldman,Saibal Kar,Michael Rinaldi,Peter S. Fail,James B. Hermiller,Richard W. Smalling,Patrick L. Whitlow,William A. Gray,Reginald I. Low,Howard C. Herrmann,Scott Lim,Elyse Foster,Donald D. Glower,Everest Investigators +13 more
TL;DR: Percutaneous repair with the MitraClip system can be accomplished with low rates of morbidity and mortality and with acute MR reduction to < 2+ in the majority of patients, and with sustained freedom from death, surgery, or recurrent MR in a substantial proportion.
Journal ArticleDOI
Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction
Audrey H. Wu,Keith D. Aaronson,Steven F. Bolling,Francis D. Pagani,Kathy Welch,Todd M. Koelling +5 more
TL;DR: There is no clearly demonstrable mortality benefit conferred by MVA for significant MR with severe LV dysfunction, and a prospective randomized control trial is warranted for further study of mortality with MVA in this population.